Ken Griffin Delcath Systems, Inc. Call Options Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$4.47 - $8.37 $9,834 - $18,414	2,200 Added 23.16%	11,700 $97,000
Q1 2024 May 15, 2024	SELL	$3.72 - $5.09 $13,020 - $17,815	-3,500 Reduced 26.92%	9,500 $45,000
Q4 2023 Feb 14, 2024	BUY	$2.25 - $4.17 $4,275 - $7,923	1,900 Added 17.12%	13,000 $54,000
Q3 2023 Nov 14, 2023	BUY	$3.12 - $5.85 $34,632 - $64,934	11,100 New	11,100 $44,000

7.84M

118K

69.9K

Ticker DCTH
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 8,597,680
Market Cap $79.1M
Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.